Objective: The aim of this study was to quantify the copies of circulating nucleophosmin (NPM) mutations DNA in the plasma of patients with acute myeloid leukemia (AML) and to explore the association of circulating NPM mutation levels with clinical characteristics. Design and Methods: The presence of NPM mutations in 100 Chinese patients newly diagnosed with AML were identified by RT-PCR and sequencing analysis. Copies of circulating NPM mutation A (NPM mut.A) DNA in the plasma of mutation-positive cases were quantified by real-time quantitative PCR (qRT-PCR). Furthermore, the association of circulating NPM mutation levels and clinical characteristics was analyzed. Results: NPM mutations were identified in 37 of the 100 patients and all cases were NPM mut.A. The circulating NPM mut.A levels ranged from 0.35×10 8 copies/ml to 6.0×10 8 copies/ml in the 37 mutation-positive cases. The medium and quartile M (P25, P75) of the circulating NPM mut.A levels in patients classified as M2, M4 and M5 morphological subtypes were 1. , 3.05×10 8 ) copies/ml, respectively. Circulating NPM mut.A levels were significantly higher in patients with the M5 subtype of AML compared to patients with the M2 and M4 subtypes (p=0.000, p=0.046). In addition, circulating NPM mut.A copies were significantly associated with a higher white blood cell count, platelet count and bone marrow blast percentage (p<0.05). Conclusion: Our results suggest that circulating NPM mutations DNA assay serves as a complementary to the routine investigative protocol of NPM-mutated leukemia.
Introduction
Circulating DNA in serum or plasma bears the same genetic and epigenetic changes as in a patient's tumor tissues, indicating the possibility of creating less-invasive diagnostic tests based on tumor-specific DNA markers [1] . A number of investigations has revealed circulating DNA to be present in higher levels in patients with cancer of the central nervous system, breast, ovarian, colon, liver, lung, prostate, pan-
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International Publisher creas and thyroid [2, 3] . Plasma samples in patients with leukemia enrich tumor-specific DNA more than in solid tumors because leukocytes exist in the peripheral blood (PB) [4] . The levels of circulating DNA in patients with hematological malignancies, such as chronic myeloid leukemia [5] , multiple myeloma [6] and myelodysplastic syndrome [7] are higher than those in healthy individuals. Our previous work showed that the concentration and integrity of circulating DNA in the plasma were significantly increased in patients with acute myeloid leukemia (AML) [8] . However, the leukemia-specific genetic markers in the plasma of patients with AML have not been investigated further.
Nucleophosmin (NPM) is the most commonly mutated gene in AML [9] . NPM mutations destroy the nucleolar localization signal of NPM and cause an abnormal cytoplasmic accumulation of it (NPMc+) [10] , which was included as a provisional entity in the revised 2008 World Health Organization (WHO) classification for AML [11] . Over 50 molecular NPM mutation variants have been identified and the most common mutation is NPM mutation A (NPM mut.A) [12] . NPM mutations are fairly stable over the course of the disease [13] . The expression of NPM mutations is associated with therapy response and are strongly predictive for impending hematological relapse [14, 15] . Furthermore, the level of NPM mutations is useful for the assessment of minimal residual disease (MRD) [16] . However, the majority of researches has focused on the detection of cellular NPM mutation in bone marrow (BM) samples.
In the present study, NPM mutations were identified from 100 patients with AML, and the number of copies of circulating NPM mutations in these positive cases were determined by quantitative real-time PCR (qRT-PCR). In addition, the association of circulating NPM mutation levels with clinical characteristics was analyzed.
Materials and Methods

Study subjects
A total of 100 primary AML diagnosed at the Southwest Hospital of the Third Military Medical University and the First Affiliated Hospital of Chongqing Medical University in China were studied. All cases were diagnosed through cytomorphology, cytogenetic, and molecular genetic analyses of BM aspirates. All patients were classified according to the French-American-British (FAB) criteria and the cases with FAB subtype M3 were not included in the trial. PB and BM specimens were collected prior to any definitive therapy. This study was conducted in a blind manner. This study has been approved by the Institutional Ethics Review Board for human studies, and all patients signed an informed consent.
Sample collection and circulating DNA isolation
Peripheral blood samples were collected into EDTA-containing vacuum tubes and processed within 24 hours. The plasma and cells samples was separated by centrifugation (3,000 g for 20 min) and stored at -80°C for analysis. Circulating DNA was isolated from 2 ml of the plasma samples using a QIAamp DNA Blood Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.
RT-PCR for NPM and sequencing for NPM mutations
The RT-PCR amplification of the NPM gene was performed in a reaction volume of 20 μl, containing 2 μl plasma DNA; according to the manual, 20 pmol of each primer (TaKaRa, Tokyo, Japan), MgCl 2 , dNTPs, Taq 1× Buffer and DNA Taq polymerase were used. The forward and reverse primers for NPM were: 5'-TTAACTCTCTGGTGGTAGAATGAA-3' and 5'-AAGTTCTCACTCTGCATTATAAAAAGGA-3', respectively. PCR amplification included denaturation at 94°C for 5 min, followed by 35 cycles of 95°C for 30 sec, 55°C for 30 sec and 72°C for 45 sec, with a final elongation at 72°C for 10 min. The amplification products were purified using the Cycle Pure Kit (Omega, Georgia, USA) and were sequenced to verify the NPM gene mutations. To validate the NPM mutation type, PCR products from the mutation-positive samples were T-A cloned into the pMD18-T vector (TaKaRa, Tokyo, Japan) and then transformed into Escherichia coli DH5α. The recombinant plasmid DNA was confirmed by sequencing for the NPM mutation types.
qRT-PCR for circulating NPM mut.A levels
The plasmid vector pEGFPC1-NPM1 mA was kindly provided by Dr. B Falini (Institute of Hematology, University of Perugia, Perugia, Italy). The plasmid DNA concentration was determined by absorbance measurement, and 10-fold serial plasmid dilutions (10 1 to 10 12 copies/ml) were prepared. Sequential dilutions were amplified by qRT-PCR to construct a standard curve for the absolute quantitative assessment of copy number. Each dilution was tested a minimum of 5 times, and standard curves were obtained by plotting the CT value versus the plasmid copy number logarithm. Then, the correlation coefficient of the standard curve was calculated. The reproducibility of this approach was reflected by the coefficients of variation (CV). For measurement of within-run variation, seven different levels of the plasmid were measured 10 times. Each measurement was performed on different days when the between-run variation was measured.
The circulating NPM mut.A levels were determined by qRT-PCR. The 20 μl reaction mixture contained 2 μl of DNA, 1 μl (0.4 μM) of sequence specific primers and 10 μl of SYBR Premix Ex Taq (TaKaRa, Tokyo, Japan). The sequences of the NPM mut.A primers were as follows: forward 5'-AGGCTATTCAA GATCTCTGTCTGG-3', and reverse 5'-AAGTTCTCA CTCTGCATTATAAAAAGGA-3'. qRT-PCR was performed on a Rotor-Gene 6000 Real-Time PCR instrument (Corbett Research, Sydney, Australia). The copies of NPM mut.A in each sample were determined using the standard curve. The mean NPM mut.A copy number was calculated from triplicate reactions. All qRT-PCR assays were performed in a blinded fashion, without knowledge of specimen identity.
Statistical analysis
The data were analyzed using the t-test and Spearman correlation test. The circulating NPM mut.A levels were summarized as medium and quartile M (P25, P75). SPSS (Version 16.0) was used for statistical analysis. A value of p<0.05 was considered statistically significant. All clinical data were collected from patient records and organized in the leukemia clinical database.
Results
Clinical information on subjects
One hundred newly diagnosed patients with AML were recruited into the present study (Table 1) . By FAB classification, 36 patients were M2, 20 were M4, 23 were M5 and 21 were other subtypes. The relevant clinical characteristics of the AML patients are summarized in Table 1 .
Identification of NPM mutations in AML patients
We identified the NPM mutation in 37 (24 females and 13 males) of the 100 samples from the AML patients (Table 2 ) and all cases were NPM mut.A, with a duplication of the TCTG tetranucleotide at position 956-959 of the reference sequence (NM_002520). As shown in Table 2 , NPM mutations were more frequent in the patients classified as M4 (9/20) and M5 (14/23) subtypes when compared with other subtypes, while the NPM mutations were not detected in patients with the M0 (0/2) and M6 (0/4) subtypes. In addition, among the 37 patients positive for NPM mutations, 35 harbored NPM mutations in the detection of PB mononuclear cells. 
Methodological evaluation of qRT-PCR for NPM mut.A
The plasmid carrying target NPM mut.A gene was successfully constructed. As shown in Fig. 1A , every dilution (10 5 ~10 11 copies/ml) of the target plasmid showed typical amplification curves. The corresponding qRT-PCR standard curve showed an ideal linear correlation between the C T values and the logarithm of the initial template concentration, with a correlation coefficient of 0.99812 (Fig. 1B) . Additionally, the repeatability of the qRT-PCR assays was estimated. The within-run and between-run CV of this qRT-PCR were 3.21% (n=10) and 4.87% (n=10), respectively.
Circulating NPM mut.A DNA in AML patients
Circulating NPM mut.A DNA levels from the 37 NPM mutation-positive cases were determined by qRT-PCR. The NPM mut.A copy numbers ranged from 0.35×10 8 copies/ml to 6.0×10 8 copies/ml. The medium and quartile M (P25, P75) of the NPM mut.A copy numbers in the cases classified as M2, M4 and M5 subtypes were 1.35×10 8 8 ) copies/ml, respectively. Circulating NPM mut.A levels were significantly higher in patients with the M5 subtype compared to patients with the M1, M2 and M4 subtypes (p=0.032, p=0.000, p=0.046), and there was no statistically significant differences in the circulating NPM mut.A lev-els between patients with the other subtypes (p>0.05). As shown in Fig. 2 . 
Circulating NPM mut.A DNA and clinical characteristics
To investigate the correlations between circulating NPM mut.A DNA and clinical characteristics, we reviewed the participants' white blood cell (WBC) counts, platelet counts, hemoglobin levels and BM blast percentages. All the laboratory parameters were categorized into two groups (low/high). The circulating NPM mut.A DNA was significantly higher in the patients with a high peripheral WBC count (>40×10 9 /L), high platelet count (>70×10 9 /L) and high BM blast percentage (>70%), compared to the patients with low values for those laboratory parameters (p=0.002; p =0.029; p=0.001), as shown in Fig. 3 . No significant correlation between circulating NPM mut.A level and hemoglobin level was found (p>0.05, data not shown). In addition, a higher NPM mut.A level was frequently found in elder patients (>60 years); there was no significant difference in NPM mut.A level between males and females (p>0.05).
Discussion
An increasing number of reports have demonstrated the molecular diagnostic value of PB circulating DNA in patients with hematological malignancies. Circulating DNA of leukemia patients is currently available but is nonspecific and has a low sensitivity. NPM gene mutations are the most common genetic alteration in AML, and the NPM mutation copies are clinically important for monitoring MRD [17, 18] . We detected the circulating NPM mut.A DNA levels and found the clinical role of circulating NPM mut.A DNA in AML. We identified NPM mutations from 100 patients with AML. Thirty-seven NPM mutation-positive cases were identified. A high NPM mutation rate was found in the patients with M4 (9/20) and M5 (14/23) subtypes, which was in accordance with the results of Falini B et al [13] . The NPM mutation was absent in patients with the M0 (0/2) and M6 (0/4) subtypes, which should be confirmed in larger studies. In the present study, we compared the NPM mutations between the plasma and PB cells. Of interest, we identified 37 of 100 AML plasma samples positive for NPM mutations, while only 35 patients identified in PB cell samples. This discrepancy was also observed in the study of Ma W et al [19] in which they identified NPM mutations in 24 of 98 AML plasma samples, while cell samples showed positivity in only 22 patients.
To quantitatively detect the circulating NPM gene mutation DNA copies, we first established the qRT-PCR assays for the detection of circulating NPM mut.A gene copies. High correlation coefficients (0.99812) allowed accurate assessment of the quantity of NPM mut.A. Good reproducibility (within-run CV of 3.21% and between-run CV of 4.87%) showed that the established qRT-PCR protocol in our study was effective. Then, circulating NPM mut.A DNA was detected and ranged from 0.35×10 8 copies/ml to 6.0×10 8 copies/ml in the 37 mutation-positive cases, and higher circulating NPM mut.A levels were found in the patients with the M5 subtype compared to the patients with M2 and M4 subtypes (p=0.000, p=0.046). Indeed, Falini B et al [20] reported that NPM gene mutations occur more frequently in M5 and M4. Furthermore, we observed the clinical relevance of circulating NPM mutations with clinical parameters according to the study of Döhner K et al [21] . We found that the circulating NPM mut.A copies in AML patients were associated with higher WBC count, higher platelet count and higher BM blast percentage. This is in agreement with previous study by Ehninger G et al [22] , which indicated that the presence of NPM mutations was associated with higher WBC count, higher platelet count and higher BM blast percentage.
In conclusion, we quantitatively detected circulating NPM mut.A gene copies by an qRT-PCR method that we established and found that elevated NPM mut.A gene copies were associated with clinical characteristics. Our data support the utility of circulating NPM mut.A DNA serves as a complementary to the routine investigative protocol of NPM-mutated leukemia. It is important to note that the sample size of our study was small, and prospective studies in large patient series are needed to evaluate further the clinical relevance of circulating NPM mut.A for therapy response and clinical outcomes. 
